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Aims Heart failure is often preceded by cardiac hypertrophy, which is characterized by increased cell size, altered protein
abundance, and actin cytoskeletal reorganization. Profilin is a well-conserved, ubiquitously expressed, multifunctional
actin-binding protein, and its role in cardiomyocytes is largely unknown. Given its involvement in vascular hypertrophy,
we aimed to test the hypothesis that profilin-1 is a key mediator of cardiomyocyte-specific hypertrophic remodelling.
Methods
and results
Profilin-1 was elevated in multiple mouse models of hypertrophy, and a cardiomyocyte-specific increase of profilin in
Drosophila resulted in significantly larger heart tube dimensions. Moreover, adenovirus-mediated overexpression of
profilin-1 in neonatal rat ventricular myocytes (NRVMs) induced a hypertrophic response, measured by increasedmyo-
cyte size and gene expression. Profilin-1 silencing suppressed the response in NRVMs stimulated with phenylephrine or
endothelin-1. Mechanistically, we found that profilin-1 regulates hypertrophy, in part, through activation of the ERK1/2
signalling cascade. Confocal microscopy showed that profilin localized to the Z-line of Drosophila myofibrils under
normal conditions and accumulated near the M-line when overexpressed. Elevated profilin levels resulted in elongated
sarcomeres, myofibrillar disorganization, and sarcomeric disarray, which correlated with impaired muscle function.
Conclusion Our results identify novel roles for profilin as an important mediator of cardiomyocyte hypertrophy. We show that
overexpression of profilin is sufficient to induce cardiomyocyte hypertrophy and sarcomeric remodelling, and silencing
of profilin attenuates the hypertrophic response.
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1. Introduction
Heart failure (HF), a leading cause of morbidity and mortality, is often
preceded by cardiac hypertrophy, a process in which cardiomyocytes
exhibit increased size, changes in protein abundance, and cytoskeletal
and sarcomeric reorganization.1 While current treatments offer thera-
peutic benefits, a greater understanding of the pathological underpin-
nings might enable more targeted modalities and improve survival.
Thus, understanding the mediators of hypertrophy remains important.
Profilins are ubiquitously expressed, multifunctional, and highly con-
served actin-binding proteins of 15 kDa.2,3 Four profilin genes have
been identified in mammals, Pfn1–Pfn4,4 while the gene family in inver-
tebrates is often less complex. In Drosophila, for example, a single pro-
filin isoform is encoded by chickadee.5 Profilins are found in different
cellular locations where they perform diverse cytoplasmic and nuclear
roles.4 Pfn1 encodes profilin-1, the isoform found in vertebrate cardiac
tissue.6 It promotes actin polymerization by catalyzing ADP to ATP ex-
change on G-actin3,7 and through transient interactions of the profilin–
ATP–actin complex with the fast-growing ‘barbed’ end of F-actin.8 Pro-
filin associates with many ligands via its poly-L-proline-binding domain,
linking it not only to proteins involved with actin polymerization, but
also to Rac and Rho effector molecules, nuclear export receptors,
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and regulators of endocytosis.3 Profilin also interacts with phosphatidy-
linositol lipids6,9,10 and transcription factors, highlighting roles in signal-
ling and gene activity.11 Its promiscuous associations with numerous
ligands underscores profilin’s connection to several diseases including
familial amyotrophic lateral sclerosis12 and to common hypertrophic
signalling pathways.13
Myofibrils of cardiac and skeletal myocytes are highly differentiated
cytoskeletal structures, in which F-actin and other contractile compo-
nents are tightly organized into individual, repetitive sarcomeric units.14
Within each sarcomere, F-actin-containing thin filaments have their
barbed ends anchored at the Z-line, whereas the slow-growing
‘pointed’ ends extend towards the centrally located M-line.15 Myofibrils
are straight and uniform in length,16 but can change upon pathological
stimuli, whereby sarcomeres are added in series. The significance in
striated muscle maintenance of actin-binding proteins that regulate
different aspects of F-actin formation and stability has been reported
for cofilin-2,17 Wdr1,18 leiomodin-2,19 and gelsolin.20 Importantly,
the latter, an actin severing and capping protein, has recently be shown
to regulate cardiac remodelling following myocardial infarction.20
It has been established that profilin-1 plays key roles in smooth mus-
cle contraction21 and vascular remodelling.13 Increased expression of
profilin-1 in vascular smooth muscle cells induced stress fibre forma-
tion, triggered ERK1/2, JNK, and Rho-associated hypertrophic signalling
cascades, and resulted in elevated blood pressure.13 Profilin-1 is highly
expressed in left ventricles of spontaneously hypertensive rats (SHRs)
and promotes cardiac hypertrophy and fibrosis by modulating actin
polymerization.22 Nevertheless, it is unclear whether this is a primary
consequence of altered profilin-1 in cardiomyocytes, or a secondary
effect in response to changes in profilin-1 in the vasculature, as
evidenced by Elnakish et al.23 who demonstrated that vascular
remodelling-associated hypertension engendered left ventricular
hypertrophy and contractile dysfunction in transgenic mice overex-
pressing profilin-1. Thus, we tested the hypothesis that cardiomyocyte
hypertrophy is accompanied by altered profilin-1 levels and that such
muscle-specific changes, in vivo, can directly modulate sarcomere
organization and independently drive cellular remodelling. Our results
reveal key roles for profilin-1 as a mediator of cardiomyocyte hyper-
trophy, as a regulator of myofibrillar and sarcomeric organization,
and as a key signalling molecule that is both necessary and sufficient
for cellular remodelling.
2. Methods
Expanded methods are available in Supplementary material online.
2.1 Animal models and fly strains
Sham-operated male C57BL/6 mice (8–11 weeks, Jackson Laboratories,
Bar Harbor, ME, USA) or mice with induced pressure-overload of the
left ventricle via transverse aortic constriction (TAC) were investigated.24
TAC was performed by tying a suture (7-0 prolene) around the transverse
aorta and a 26-gauge needle. In addition, Gaq-overexpressing FNB/N male
mice (4–5 months) and non-transgenic controls were used.25 Details on
anaesthesia, analgesia, and euthanasia are described in Supplementary ma-
terial online. Protocols were approved by the Johns Hopkins Medical Insti-
tutions Animal Care and Use Committee, and the animal experiments that
were performed conform to the NIH guidelines.
Flies were raised and crossed at 258C according to standard procedures.
‘Profilin-1’ denotes the mammalian isoform and ‘profilin’ the Drosophila
homologue. The following fly stocks were used: w; CyO;P[UAS + chicE1]
78.3 (UAS-Pfn_1) and w; CyO;P[UAS + chicE1]36.5 (UAS-Pfn_2) (kind gifts
of Dr Lynn Cooley, Yale University),26 gw; Dmef2-GAL4 (Bloomington
Stock Center), w, UH3-GAL4 (kind gift of Dr Upendra Nongthomba, Indian
Institute of Science),27 w; Hand-GAL4 (Bloomington Stock Center), gn;
UAS-ChicRNAi (y1 sc* v1; P{TRiP.HMS00550}attP2, Bloomington Stock
Center).
The GAL4-upstream activator sequence (UAS) system was utilized for
targeted Drosophila gene expression, in which the yeast GAL4 transcription
factor activates transcription of its target genes by binding to UAS cis-
regulatory sites.28 The combination of two transgenic fly lines (UAS-Pfn_1
and UAS-Pfn_2) with two muscle driver lines (Mef2-GAL4 and UH3-
GAL4) created a genotypically diverse range of profilin overexpression
and content among offspring. Progeny of w1118 or gw flies crossed with
the appropriate driver line served as controls. Adult flies were used for
all experiments. Ten hours after emerging from puparia, adult female flies
are sexually mature, begin to breed, and lay eggs.
2.2 Western blot analysis
Western blot analysis was done according to standard protocols. Western
blots of tissue from mice and Drosophila were corrected for loading using
Direct Blue 71- or Pierce Reversible Protein Stain-stained membranes.
For this purpose, intensity over the entire lane was averaged.
2.3 Viral transfection, RNA interference, and
RNA isolation from neonatal rat ventricular
myocytes
Neonatal rat ventricular myocytes (NRVMs) were Isolated and then cul-
tured from 1- to 2-day-old Sprague–Dawley rats as previously described.29
Overexpression of profilin-1 was achieved via adenovirus-mediated trans-
fection. Ad-mCherry-mPFN1 and Ad-mCherry (Adenoviral Type 5, CMV
promoter) were purchased from Vector Biolaboratories (Burlingame,
CA, USA). NRVMs were transfected using a multiplicity of infection of 10
for 24 h. RNAwas harvested 24 h after and protein 48 or 72 h after transfec-
tion. For RNA interference, ON-TARGET and SMART pool reagent against
Pfn1 (L-092311-02) were purchased from Dharmacon (Lafayette, CO, USA).
ON-TARGET and Non-targeting pool (D-001810-10-05, Dharmacon) were
used as a non-specific control. Twenty-four hours after plating, NRVMs were
transfected with 25 nM siRNA using DharmaFECT 1 (Dharmacon) following
the manufacturer’s protocol. The next day, cells were treated with 20 mM
phenylephrine (PE) or 100 nMendothelin-1 (ET1). RNA isolation is described
in detail in Supplementary materials online.
2.4 Confocal microscopy and EM
Mouse myocardium was fixed with 10% formalin, paraffin-embedded, and
sectioned into 4 mm slices. Indirect flight muscles (IFMs) from 2- to
3-day-old adult flies were dissected from bisected half thoraces and fixed
in 4% paraformaldehyde overnight. Samples were labelled for confocal mi-
croscopy according to standard techniques.24,30 Composite averaged con-
focal images of consecutiveDrosophila IFM sarcomeres were created using a
novel ImageJ-based approach. EM of IFM was conducted as reported previ-
ously.31 Complete details regarding sample processing, staining, and imaging
procedures can be found in Supplementary material online.
2.5 Drosophila flight and climbing tests,
and image analysis of beating hearts
Flight and climbing tests were carried out on 2–3-day-old adult flies. Car-
diac tubes of 3-week-old female adult flies were surgically exposed accord-
ing to Vogler and Ocorr32 High-speed movies of semi-intact Drosophila
preparations were acquired for image analysis of heart contractions as pre-
viously described.30,33 Thirty-second movies were taken at 120 frames
per second using a Hamamatsu Orca Flash 2.8 CMOS camera on a Leica
DM5000B TLmicroscopewith a×10 immersion lens. M-mode kymograms
were generated, and physiological parameters assessed, using a MATLAB-
based image analysis program.34
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2.6 Statistics
Prism 5 (GraphPad Software) was used for statistical analyses and graphical
presentations. Statistical tests employed are described in figure legends.
3. Results
3.1 Mammalian hypertrophic hearts
are characterized by increased profilin-1
content
To determine whether profilin-1 abundance in the heart is altered in
different animal models of cardiac hypertrophy and HF, western blot
analysis was performed on ventricular tissues from mice that under-
went TAC (Figure 1A and see Supplementary material online, Figure
S1A)35 and from Gaq-overexpressing mice and appropriate controls
(Figure 1B and see Supplementary material online, Figure S1A).25 Rela-
tive to total protein, profilin-1 levels were 2.5-fold higher in the TAC
group (0.40+ 0.06 a.u., n ¼ 10) compared with the control group
(0.16+ 0.04 a.u., n ¼ 5). TAC animals additionally demonstrated car-
diac dysfunction (see Supplementary material online, Figure S1B). More-
over, cardiac tissue obtained from Gaq-overexpressing mice showed
significantly increased levels of profilin-1 (0.35+0.02 a.u., n ¼ 7) com-
pared with controls (0.27+0.02 a.u., n ¼ 3). NRVMs were isolated to
assess cardiomyocyte-specific expression levels of Pfn1 (profilin-1) in
cells treated with PE or ET1 to stimulate hypertrophy. Pfn1 transcripts
were significantly increased after stimulation with 20 mM PE for 24 h
(1.7+0.22, n ¼ 6) compared with unstimulated NRVMs (1.0+0.05,
n ¼ 6; Figure 1C), and also in NRVMs treated with 100 nM ET1
(1.3+ 0.12, n ¼ 6) relative to controls (1.0+0.08, n ¼ 6; see Supple-
mentary material online, Figure S1C). Furthermore, profilin-1 was sig-
nificantly more abundant after PE treatment (2.0+ 0.08, n ¼ 6)
compared with untreated controls (1.1+ 0.08, n ¼ 6). To define the
gross localization of profilin-1, sectioned cardiac tissue from control
mice was subjected to anti-profilin-1 antibody, DAPI, and TRITC-
phalloidin staining. Confocal images showed a striated profilin-1 signal,
which implies the protein associates recurrently along sarcomeres
(Figure 1D). This is consistent with earlier results,6 confirming the pres-
ence of profilin-1 in cardiomyocytes, and repetitive occupancy of
profilin-1 along myofibrils. Cardiac tissues from explanted hearts of pa-
tients with end-stage HF (Failing) contained decreased PFN1 transcript
levels (0.55+ 0.04 a.u. n ¼ 9) compared with donor hearts (Healthy,
1.05+ 0.21 a.u., n ¼ 8; see Supplementary material online, Table S1
and Figure S1D). The discrepancy in profilin-1/Pfn-1/PFN1 levels be-
tween the hypertrophic hearts and human end-stage failing hearts
may be due to differences in disease and diseased (e.g. compensated
vs. decompensated) state.
3.2 Cardiomyocyte-specific overexpression
of profilin induces cardiomyopathy in
Drosophila
To investigate cardiomyocyte-restricted effects of increased profilin
expression in vivo, and to assess whether elevated profilin quantity is
Figure 1 Increased expression of profilin-1 in hypertrophic cardiomyocytes. (A) Pressure-overload following TAC resulted in elevated levels of
profilin-1 in mouse hearts. Protein levels were corrected for total gel loading (see Supplementary material online, Figure S1A). Representative actin bands
from Direct Blue 71-stained membranes are shown. A significant increase in profilin-1/total protein was observed in the myocardium of the TAC vs.
Sham group (n ¼ 5–10, *P, 0.05; Student’s t-test). (B) A hypertrophic/HF mouse model overexpressing wild-type Gaq showed higher levels of cardiac
profilin-1 compared with control (n ¼ 3–7, *P, 0.05; Student’s t-test). Protein levels were corrected for total gel loading (see Supplementary material
online, Figure S1A). Representative actin bands from Direct Blue 71-stained membranes are shown. (C) PE treatment in NRVMs increased Pfn1 mRNA
(n ¼ 6, *P, 0.05; Student’s t-test) and profilin-1 (n ¼ 6, ***P, 0.001; Student’s t-test) content. (D) Representative confocal images of control murine
cardiac tissue show profilin-1 repetitively associates with myofibrils in a striated manner. Scale bar, 10 mm.
V. Kooij et al.240
by guest on April 21, 2016
D
ow
nloaded from
 
sufficient to alter contractile performance and/or cardiac dimensions
in a tissue-specific manner, two independent transgenic fly lines
(UAS-Pfn_1 and UAS-Pfn_2) were crossed with flies harbouring the
heart-specific Hand-GAL4 (HG4) driver (Figure 2A). Cardiac-restricted
overexpression of profilin in the progeny resulted in significantly re-
duced heart periods (HG4 . Pfn_1 464+ 23 ms, n ¼ 31; HG4 .
Pfn_2 421+ 21 ms, n ¼ 30), which indicated increased heart rate,
compared with control (553+ 30 ms, n ¼ 28; Figure 2B). Diastolic
diameters were significantly enlarged in HG4 . Pfn_1 (66+ 2 mm,
n ¼ 31) and HG4 . Pfn_2 (71+ 1 mm, n ¼ 30) relative to control
(60+ 1 mm, n ¼ 28) flies, as were systolic diameters in HG4 .
Pfn_2 (43+ 1 mm, n ¼ 30) compared with control (38+ 2 mm,
n ¼ 28; Figure 2B). Knockdown of profilin in cardiomyocytes (HG4.
PfnRNAi) was maladaptive and resulted in lethality, as flies did not eclose
from their puparia. These data suggest that profilin is essential for adult
Drosophila cardiac development, and that its overexpression induces a
phenotype reminiscent of eccentric hypertrophy.36
3.3 Myocyte-specific overexpression
of profilin impairs muscle function and
ultrastructure
To further index myopathic effects associated with elevated profilin le-
vels, transgenic Drosophila overexpressing Pfn_1 and Pfn_2 throughout
the somatic musculature were established using the Mef2-GAL4 driver
line. Mef2 . Pfn_1 flies (n ¼ 5) exhibited a significant, 17-fold in-
crease of profilin, whereas Mef2 . Pfn_2 flies (n ¼ 5) showed an
8-fold increase compared with controls (Figure 3A). Actin/myosin
heavy chain (MHC) ratio and individual intensity values normalized to
total intensity, determined by densitometric analysis of Coomassie-
stained protein bands, were not altered in these flies (Figure 3A and
see Supplementary material online, Figure S2). Muscle performance
was evaluated in 2-day-old flies using flight and climbing assays. Elevated
profilin eliminated flight and reduced climbing abilities (control
14.91+ 0.50 cm, n ¼ 64; Mef2 . Pfn_1 9.29+ 0.56 cm, n ¼ 48;
Mef2 . Pfn_2 9.43+ 0.58 cm, n ¼ 35; Figure 3B). Furthermore, IFM-
specific overexpression of profilin via UH3-GAL427 reduced, but did
not completely abolish flight ability compared with control animals
(control 5.11+ 0.17 a.u., n ¼ 83; UH3 . Pfn_1 1.43+ 0.19 a.u.,
n ¼ 74; UH3. Pfn_2 2.30+0.39 a.u., n ¼ 54; Figure 3C).
Due to an extremely well-organized myofilamentous lattice,
Drosophila IFM myofibrils are highly amenable to structural analysis.
To ascertain if profilin overexpression produced ultrastructural abnor-
malities, we examined IFMs of 2-day-old control andMef2 . Pfn_1 flies
by transmission EM (Figure 3D). Transverse sections through the IFM
revealed that the double hexagonal lattice of thick and thin filaments
in Mef2 . Pfn_1 flies was disorganized relative to control. Closer
examination revealed filament loss around the periphery of the
Mef2 . Pfn_1 myofibrils (inset), which was not observed in control
flies. Moreover, elevated profilin perturbed sarcomeric Z- and M-line
appearance and increased sarcomere lengths (control 2.75+
0.04 mm, n ¼ 20; Mef2 . Pfn_1 3.00+ 0.03 mm, n ¼ 20). Reduced
profilin expression using either the Mef2-GAL4 or UH3-GAL4 driver
lines in conjunction with UAS-PfnRNAi prevented adult Drosophila
emergence from their respective pupal cases. This underscores the
fundamental importance of profilin for muscle development.
3.4 Elevated profilin results in elongated
thin filaments and sarcomeres and its
accumulation at the centre of the sarcomere
To verify an effect of muscle-restricted profilin overexpression on thin
filament and sarcomere lengths,Drosophila IFMmyofibrils were labelled
with anti-a-actinin antibody, a Z-line protein, and TRITC-phalloidin, im-
aged via confocal microscopy, and dimensions ascertained (see Supple-
mentary material online, Figure S3A). Increased expression of profilin via
theMef2-GAL4 driver (Figure 3A) resulted in significantly elongated thin
filament (Mef2 . Pfn_1 1.42+ 0.01 mm, n ¼ 255; Mef2 . Pfn_2
1.41+ 0.01 mm, n ¼ 252) and sarcomere lengths (Mef2 . Pfn_1
3.57+ 0.01 mm, n ¼ 106; Mef2 . Pfn_2 3.59+ 0.01 mm, n ¼ 116)
Figure 2 Cardiomyocyte-specific overexpression of profilin inDrosophila induces cardiomyopathy. (A) Representative M-mode kymograms generated
from high-speed videos of beating control, Pfn_1, and Pfn_2 heart tubes. DD, diastolic diameter; SD, systolic diameter; HP, heart period. (B) Semi-
automated optical heartbeat analysis from flies overexpressing profilin via the HG4 cardiac-specific driver revealed significant reductions in heart period
and increased cardiac dimensions relative to control (n ¼ 28–30, *P, 0.05, **P, 0.01 and ***P, 0.001; Kruskal–Wallis test with Dunn’s post hoc test
for HP and SD analysis; one-way ANOVA with the Bonferroni post hoc test for DD analysis).
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compared with control thin filament (1.25+ 0.01 mm, n ¼ 255) and
sarcomere lengths (3.29+ 0.01 mm, n ¼ 114; Figure 4A). These results
are consistent with significantly increased sarcomere lengths measured
from electron micrographs (Figure 3D) and were confirmed in flies
overexpressing profilin in the IFM using the UH3-GAL4 driver line
(thin filament: control 1.28+ 0.01 mm, n ¼ 274; UH3 . Pfn_1
1.46+ 0.01 mm, n ¼ 274; UH3 . Pfn_2 1.42+ 0.01 mm, n ¼ 271;
sarcomere lengths: control 3.31+ 0.01 mm, n ¼ 274; UH3 . Pfn_1
Figure 3 Overexpression of profilin in Drosophila IFM impairs muscle function and ultrastructure. (A) Western blot analysis showed increased profilin in
wholeMef2. Pfn_1 andMef2. Pfn_2 transgenic flies (top) (n¼ 5, *P, 0.05, **P, 0.01; one-way ANOVAwith the Bonferroni post hoc test). Actin/myosin
heavy chain ratios remained unchanged in flies with muscle-restricted profilin overexpression compared with control (bottom) (n ¼ 5). (B) Two-day-old
Mef2. Pfn_1 and Mef2. Pfn_2 flies were unable to fly and demonstrated significantly reduced climbing ability (n¼ 35–64, ***P, 0.001; Kruskal–Wallis
test with Dunn’s post hoc test). (C) UH3-GAL4-mediated overexpression of profilin significantly diminished flight ability (n ¼ 54–83, ***P, 0.001; one-way
ANOVAwith the Bonferroni post hoc test). (D) Representative electron micrographs of transverse sections of Mef2. Pfn_1 IFMs (top) show that the double
hexagonal lattice of myofilament arrangement was less ordered and thin and thick filaments were missing on the outer edges of the myofibril (inset) relative to
control. Moreover, therewas Z-band buckling andM-line distortion in longitudinal sections (bottom). Single arrowheads delineate anM-line and double arrow-
heads a Z-line. MT, mitochondrion; MF, myofibril. Scale bars, 500 nm and 250 nm for longitudinal and transverse sections, respectively, and 50 nm in the inset.
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3.61+0.01 mm, n ¼ 98; UH3 . Pfn_2 3.63+ 0.01 mm, n ¼ 104; see
Supplementary material online, Figure S3B).
To resolve the sarcomeric localization of profilin, half thoraces from
control flies were labelled with TRITC-phalloidin, anti-profilin anti-
body, and with an anti-MHC antibody that labels the H-zone/M-line re-
gion of IFM myofibrils. Confocal images of myofibrils demonstrated
that profilin localized predominantly to the Z-line of the sarcomere un-
der basal conditions, a position expected due to its known association
with the barbed end of F-actin (Figure 4B). Myofibrils from both Mef2.
Pfn_1 and Mef2 . Pfn_2 overexpressors, however, showed profilin at
the Z-line and a significant accumulation at a position towards the thin
filament pointed end/H-zone (Figure 4B). The average of the ratios of
the maximum profilin intensity at each pointed end/H-zone to the
maximum profilin intensity at the neighbouring Z-line was significantly
higher for Mef2 . Pfn_1 (1.03+ 0.02, n ¼ 123) and Mef2 . Pfn_2
(0.85+ 0.02, n ¼ 143) myofibrils compared with control (0.66+
0.02, n ¼ 138; Figure 4C). In summary, data generated using theDrosoph-
ilamodel illustrate that myocyte-restricted overexpression of profilin is
Figure 4 Elongated thin filaments and sarcomeres in flies overexpressing profilin. (A) Left: increased IFM thin filament (n¼ 252–255, ***P, 0.001; one-way
ANOVA with the Bonferroni post hoc test) and sarcomere lengths (n¼ 106–116, ***P, 0.001; one-way ANOVA with the Bonferroni post hoc test) were
measured in flies with Mef2-GAL4-driven profilin overexpression. Right: typical IFM sarcomeres for control and profilin-overexpressing flies (red,
TRITC-phalloidin-stained thin filaments; yellow, anti-a-actinin-stained Z-lines). (B) Averaged composite images of consecutive IFM sarcomeres from flies
with elevated profilin levels revealed localization at the Z-line and at the thin filament pointed end/H-zone, whereas controls predominantly showed profilin
localization at the Z-line. TheM-line/H-zonewas labelled using anMHCantibody that recognizes the centre of thick filaments along IFMmyofibrils. (C) Based on
normalized fluorescence intensity, Mef2. Pfn_1 and Mef2. Pfn_2 transgenic flies had significantly more profilin at the M-lines/H-zones, proximal to the thin
filament pointed ends, relative to that at the Z-lines comparedwith controls (n¼ 123–143, ***P, 0.001; one-way ANOVAwith the Bonferroni post hoc test).
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sufficient to induce sarcomeric and myofibrillar remodelling, muscle
dysfunction, and myopathy.
3.5 Adenoviral overexpression of profilin-1
induces a hypertrophic response in NRVMs
Adenoviral-mediated profilin-1 overexpression in NRVMs resulted in
significant increases in Pfn1 mRNA (n ¼ 12) and protein (n ¼ 6) levels
(Figure 5A and B) compared with controls (Adv-Control). Increased le-
vels of profilin-1 resulted in elevation of the hypertrophic fetal gene
markers atrial natriuretic peptide (ANP) and brain natriuretic peptide
(BNP) (Figure 5C). Additionally, increased cell size, another hallmark of
hypertrophy, was measured in cells transfected with Adv-Profilin-1
(6387+ 317 mm2, n ¼ 33) compared with Adv-Control (5207+
260 mm2, n ¼ 33; Figure 5D). Both adenoviruses expressed mCherry
under the control of the CMV promoter to determine transfection
Figure 5 Adenoviral-mediated overexpression of profilin-1 induces a hypertrophic response in NRVMs. (A) Transcript levels of Pfn1 in NRVMs were
significantly higher than control following adenoviral-mediated transfection (n ¼ 12, ***P, 0.001; Student’s t-test). (B) Pfn1 overexpression resulted in
significantly increased levels of profilin-1 (n ¼ 6, ***P, 0.001; Student’s t-test). (C) Elevated Pfn1 expression resulted in increased transcript levels of the
hypertrophic markers ANP and BNP (n ¼ 12, *P, 0.05; Student’s t-test). (D) NRVMs exhibited significantly larger cellular areas in response to Pfn1
overexpression (n ¼ 33, **P, 0.01; Student’s t-test). (E) Representative profilin-1 and a-actinin antibody-stained confocal images of Adv-Control-
and Adv-Profilin-1-transfected NRVMs. Scale bar, 15 mm. (F ) A ×3.1 zoom of confocal images of Adv-Profilin-1-transfected cells (white box in the
merged image). Scale bar, 5 mm.
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efficiency. Figure 5E shows representative images of profilin-1 and
a-actinin in NRVMs transfected with Adv-Profilin-1 and Adv-Control.
Profilin-1 frequently exhibited repetitive occupancy along NRVMmyo-
fibrils (Figure 5F). These results indicate that overexpression of
profilin-1 in NRVMs is sufficient to induce cellular hypertrophy.
3.6 Suppression of Pfn1 gene expression
attenuates hypertrophic signalling in
NRVMs
Profilin-1 protein and mRNA levels are increased compared to appropri-
ate controls following TAC, in Gaq-overexpressing mouse hearts, and in
PE/ET1-stimulated NRVMs, respectively (Figure 1A–C). Likewise, when
overexpressed exclusively in Drosophila cardiomyocytes, profilin pro-
moted eccentric hypertrophy (Figure 2). To further test if increased
profilin-1 is vital to the cardiac hypertrophic response, we expressed
Pfn1 siRNA in NRVMs and subsequently exposed the cells to PE or
ET1. siRNA-directed Pfn1 silencing was confirmed by confocal micros-
copy (Figure 6A) and western blot analysis (Figure 6B). In addition, reduced
and elevated Pfn1mRNA levels verified the cellular responses to Pfn1 siR-
NA and post PE treatment, respectively (Figure 6C). PE resulted in
significantly larger cells (3372+266 mm2, n ¼ 20) compared with con-
trol (1790+138 mm2, n ¼ 26; Figure 6C). Myocytes treated with Pfn1
siRNA and then PE had an increased surface area/size (2308+135 mm2,
n ¼ 21) comparedwith unstimulated Pfn1 siRNA cells (1668+122 mm2,
n ¼ 29). However, theywere significantly smaller than PE-stimulated con-
trols (3372+266 mm2, n ¼ 20).Moreover, ANP, BNP, and skeletal mus-
cle actin were significantly decreased in cells treated with Pfn1 siRNA
followed by PE stimulation compared with control cells. These findings
were corroborated using ET1 stimulation of NRVMs in conjunction
with Pfn1 silencing (Figure 6D). Our results indicate that profilin-1 contri-
butes to hypertrophy-induced cell growth.
To elucidate the signalling pathway involved in profilin-1-mediated
cardiomyocyte-specific remodelling, we evaluated the activity of two
major transcription factors (NFAT andMEF2) that govern the stress re-
sponse during cardiac hypertrophy.37 Activity was measured using luci-
ferase assays with the regulator of calcineurin (RCAN, an upstream
regulator of NFAT) and MEF2 reporters. Following incubation with
Pfn1 siRNA and PE, RCAN and MEF2 luciferase signals were not
reduced (n ¼ 5), suggesting the profilin-1-associated hypertrophic re-
sponse relies on alternative signal transduction pathways (Figure 7A).
Next, involvement of the mitogen-activated protein kinase (MAPK)
Figure 6 Silencing of Pfn1 attenuates hypertrophic signalling in NRVMs. (A) Representative confocal images of control and PE-stimulated NRVMs.
NRVMs were treated with control siRNA or Pfn1 siRNA. Nuclei were stained with DAPI (blue). Profilin-1 was dramatically reduced in response to
Pfn1 siRNA. Scale bar, 10 mm. (B) Western blot analysis showed significantly decreased profilin-1 levels after the treatment of NRVMs with Pfn1 siRNA
(n ¼ 3, ***P, 0.001; two-way ANOVA with the Bonferroni post hoc test). (C) Transcript levels of Pfn1 in PE-stimulated NRVMs were increased com-
pared with control, and treatment with Pfn1 siRNA significantly reduced mRNA levels (n ¼ 4, *P, 0.05, **P, 0.01, and ***P, 0.001; two-way
ANOVAwith the Bonferroni post hoc test). Cell surface area increased significantly upon treatment with PE and was diminished upon profilin-1 silencing
(n ¼ 20–29, *P, 0.05 and ***P, 0.001; two-way ANOVA with the Bonferroni post hoc test). Transcription of the hypertrophic markers ANP,
BNP, and skeletal muscle actin was significantly reduced after Pfn1 silencing in PE treated cells (n ¼ 4, *P, 0.05, **P, 0.01, and ***P, 0.001; two-way
ANOVAwith the Bonferroni post hoc test). (D) NRVMs that were treated with Pfn1 siRNA and stimulated with ET1 exhibited significantly reduced ANP,
BNP, and skeletal a-actin mRNA levels compared with control siRNA-treated cells (n ¼ 3, *P, 0.05, **P, 0.01, and ***P, 0.001; two-way ANOVA
with the Bonferroni post hoc test).
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hypertrophic signalling pathway was tested. The amount of phosphory-
lated JNK and p38 was not significantly different among the groups and
thus did not appear to be involved (n ¼ 3; Figure 7B). However, acti-
vated (phosphorylated active sites) levels of ERK1/2 (Thr 202/Tyr
204) and Raf (Ser 338) were significantly reduced in cells treated
with PE and Pfn1 siRNA compared with control PE-treated cells, indi-
cating that profilin-1 is likely involved in the ERK1/2 MAPK hypertroph-
ic signalling pathway (n ¼ 3; Figure 7C). Consistent with this result, we
measured reduced transcript levels of two downstream genes, IL-6 and
CTGF, of the ERK1/2 signalling pathway upon silencing of Pfn1 in cells
stimulated with PE (Figure 7D) and ET1 (see Supplementary material
online, Figure S4). Particular proteins, collagens, actin isoforms, and
actin-binding proteins, however, remained unaltered following PE
stimulation in cardiomyocytes with profilin-1 knockdown (see Supple-
mentary material online, Figure S5A–C).
4. Discussion
Our results, obtained using a combination of diverse but complemen-
tary model systems, reveal key roles for profilin as a potent mediator of
cardiomyocyte hypertrophy, as a regulator of myofibrillar and sarco-
meric organization, and as a signalling molecule. Profilin-1 expression
was increased in left ventricles of mice hearts with cardiac dysfunction.
Consistent with this, cardiomyocyte-specific elevation of profilin in
the Drosophila heart tube increased cardiac dimensions, and overex-
pression of profilin-1 in NRVMs induced a hypertrophic response.
Mechanistically, we found that elevated expression resulted in elon-
gated thin filaments and sarcomeres, led to dysfunctional and disrupted
myofibrils in fly muscle and, that in vertebrate cardiomyocytes,
profilin-1 regulated hypertrophy through activation of the ERK1/2
signalling cascade.
4.1 Cardiomyocyte-specific expression
of profilin-1
Recently, Zhao et al.22 demonstrated that profilin-1 was highly ex-
pressed in left ventricles of hearts isolated from SHRs. The authors
used adenovirus tail vein injections to knockdown or overexpress
profilin-1 ubiquitously. Global knockdown of profilin-1 in SHRs attenu-
ated cardiac hypertrophy, while overexpression promoted it. It re-
mained unclear, however, whether hypertrophy was a response to
cardiomyocyte-specific increases of profilin-1 and/or vascular-specific
remodelling due to increased Pfn1 expression in smooth muscle or
endothelial cells. Our data extend these findings and confirm an in-
crease of profilin-1 in two different mouse models of hypertrophy
Figure 7 Profilin-1 is involved in the ERK1/2 signalling pathway. (A) The transcriptional activity of RCAN andMEF2 significantly increased when cells were
stimulated with PE. Activity did not decrease upon silencing of profilin-1 (n ¼ 5, **P, 0.01 and ***P, 0.001; two-way ANOVAwith the Bonferroni post
hoc test). (B) Phosphorylation levels of JNK (corrected for total JNK) and p38 (corrected for total p38) were unaltered by Pfn1 silencing and PE treatment
(n ¼ 3, two-way ANOVAwith the Bonferroni post hoc test). (C) Phosphorylation of ERK1/2 (corrected for total ERK1/2) and Raf (corrected for GAPDH)
was significantly increased in hypertrophic NRVMs and reduced upon diminished profilin-1 expression (n ¼ 3, *P, 0.05 and **P, 0.01; two-way ANOVA
with the Bonferroni post hoc test). (D) PE-increased mRNA levels of IL-6 and CTGF, effector genes of the ERK1/2 signalling cascade, were significantly re-
duced upon silencing of Pfn1 (n ¼ 3, *P, 0.05, **P, 0.01, and ***P, 0.001; two-way ANOVA with the Bonferroni post hoc test).
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and HF, indicating that expression of profilin-1 is up-regulated two- to
three-fold in cardiomyocytes independent of disease stimuli. We add-
itionally observed a cardiomyocyte-specific increase in Pfn1 mRNA in
cell models of hypertrophy, and overexpression of profilin-1 was suffi-
cient to induce a hypertrophic response. Thus, our data verify that ele-
vated levels of profilin-1 in failing hearts are, at least in part, due to
cardiomyocyte-restricted expression changes. We cannot conclude,
however, whether increased profilin levels in vivo are causal or second-
ary to cardiac dysfunction.
4.2 Altered sarcomeric structure due
to profilin overexpression
To discern sub-sarcomeric localization of profilin, we imaged Drosoph-
ila IFM myofibrils. Drosophila IFM comprises extremely well-organized
myofibrils that are comparable to those found in myocardium. IFM
function can easily be tested by evaluating flight ability, and because
of the highly organized fibrillar nature of the muscle, defects in myofi-
brillar and sarcomeric organization are readily observable. Experiments
were performed using two transgenic fly lines (UAS-Pfn_1 and
UAS-Pfn_2) with two muscle driver lines (Mef2-GAL4 and UH3-
GAL4) to obtain a range of muscle-restricted profilin overexpression
levels. This helped distinguish profilin-induced effects from potential
non-specific actions. Since all genotypic combinations of fly strains de-
monstrated similarly afflicted myocytes, profilin apparently promotes
distinct alterations to myofibrillar function and structure regardless
of the level of overexpression. However, we cannot completely ex-
clude the possibility that excessively high overexpression, using the
Mef2-Gal4 driver, may have introduced imperceptible, non-specific
events. We detected profilin localized predominantly to the Z-line in
adult control sarcomeres and to the Z- and the pointed end/M-line re-
gion when overexpressed. Moreover, elevated levels of profilin re-
sulted in elongated sarcomeres and thin filaments. Similar results
were obtained by Bai et al.38 for the actin-binding, WH2-domain-
containing protein sarcomere length short (SALS), indicating it too is
required for proper sarcomere length. SALS localized to the pointed
ends of growing thin filaments, but near the Z-line in mature muscle.38
Interestingly, SALS contains proline-rich profilin-binding sequences,
which suggests that it may work with profilin to induce thin filament
elongation from the pointed ends. Overexpression of SALS also pro-
moted filament growth by potentially antagonizing Tmod capping activ-
ity.38 Since thin filament lengths are inversely proportional to the
extent of Tmod-mediated capping,39,40 excessive profilin may help re-
cruit SALS to the pointed ends of mature thin filaments, disrupt T-mod
capping, and promote elongation via an ‘annealing mechanism’ as re-
cently proposed for DAAM, a sarcomere-associated actin assembly
factor, and a member of the formin family.41 Furthermore, high profilin
levels are associated with disruptedmyofilament packing, order, and in-
tegrity (Figure 3D, inset) and consequently impaired muscle function.
Abnormalities and disarray in myofibrillar structure are also found in
hypertrophic and failing hearts.42
4.3 Role of profilin-1 during hypertrophy
Drosophila has proved to be an efficient and effective model to study
cardiomyopathy.43 Recent evidence reveals that deficits in conserved
contractile components in flies induce pathological phenotypes re-
markably similar to those that characterize human heart disease.30,31,44
A main advantage of this model is that it allows the role of profilin to be
studied exclusively in the intact heart. Cardiomyocytes expressing
elevated quantities of profilin resulted in cardiomyopathy characterized
by increased cardiac dimensions, reminiscent of mammalian eccentric
hypertrophy.36 This indicates that increased amounts of profilin are suf-
ficient to induce a hypertrophic phenotype, which was confirmed in
NRVMs, a widely acceptedmodel for investigating cellular hypertrophy.
To elucidate whether profilin-1 is also necessary for hypertrophy, we
employed NRVMs in conjunction with Pfn1 silencing. PE-induced
hypertrophy of NRVMswas characterized by increased cell dimensions
and fetal gene re-expression. This maladaptive hypertrophic response
was significantly attenuated upon suppression of Pfn1. Up-regulation of
fetal gene expression occurs as an early immediate response and was
observed after 24 h of PE treatment. This indicates that profilin-1 is re-
quired, potentially during an initial phase at the onset of cellular remod-
elling, for cardiomyocyte hypertrophy.
Profilins perform a host of molecular roles by interacting with di-
verse partners throughout the cell;3 thus, we propose they mediate
cardiac hypertrophy via numerous interrelated mechanisms. For ex-
ample, elevated profilin-1 and altered thin filament and sarcomeric
structure can directly affect the generation and propagation of con-
tractile stress. Such mechanical changes are considered a trigger for
cardiac remodelling by potentially modulating nodal signalling mole-
cules throughout the myocyte cytoarchitecture.45,46 Profilin-1 may
also stimulate common hypertrophic signalling cascades within cardio-
myocytes including the MAPK pathway, consistent with our findings
that reduced activation of ERK1/2, Raf, and transcription of the down-
stream genes CTGF and IL-6 correlated with silencing of Pfn1 translation.
Similar results were obtained using vascular smoothmuscle cells, which
also showed ERK1/2-associated hypertrophy.13,47 Involvement of the
MAPK pathway is consistent with multiple studies that have revealed
the Ras/Raf/MEK1/ERK signalling pathway routinely promotes hyper-
trophy.48 While our data suggest that profilin-1 works upstream of
Ras, we cannot conclude it activates ERK signalling through direct inter-
actions with the small GTPases. However, several profilin ligands are
well-known Rac and Rho effector molecules, which may assist in initi-
ating the hypertrophic signal transduction pathway. Moreover, the
hearts of transgenic mice overexpressing Gaq, which showed in-
creased profilin abundance concomitant with hypertrophy, were
previously characterized by reduced PIP2 levels that enhanced cardio-
myocyte apoptosis and subsequent HF.46 Profilin-1 can bind PIP2 dir-
ectly, and elevated levels may disproportionately deplete the
phosphatidylinositol lipid, affect its availability for signal transduction,
and contribute to cardiac remodelling. Finally, profilin can bind to
and regulate the activity of the transcription factor p42POP, which is
abundantly expressed in the heart.11 Elevated profilin levels may con-
sequently markedly repress gene activity that directly or indirectly pro-
motes cardiac remodelling. Overall, our study reveals complex
functions of profilin as a modulator of sarcomeric organization and
as a mediator of hypertrophic cardiomyocyte remodelling. Therefore,
profilin-1 represents a potential therapeutic target to mitigate multiple
aspects of hypertrophy directly, in both the myocardium and in the
vasculature, during HF.
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Supplementary material is available at Cardiovascular Research online.
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